Active Surveillance for Prostate Cancer: Switch After 4 Years

Active surveillance instead of immediate aggressive treatment has become a standard of care for men with low-risk prostate cancer, and this initial management strategy has become increasing popular in recent years, show new data from a real-world study.   The study examined data on 17,000 men diagnosed with low-risk prostate cancer in Ontario, Canada between January 1, 2008 and December […]

Read more

Early ADT May Not Up OS in Prostate Cancer With PSA Relapse

Early initiation of continuous androgen-deprivation therapy (ADT) for prostate cancer patients who experience biochemical relapse may not meaningfully improve overall survival, according to new findings. A retrospective analysis with data from two institutions found that metastasis-free survival and overall survival were quite long among those who delayed hormone therapy. Among patients who experienced biochemical recurrence and whose prostate-specific antigen (PSA) […]

Read more

Androgen Blockers Likely Boost Survival in Older Men With Nonmetastatic CR Prostate Cancer

NEW YORK (Reuters Health) – Androgen receptor inhibitors improved survival in men ages 80 and older with non-metastatic, castration-resistant prostate cancer in a pooled analysis by the US Food and Drug Administration. “Older adults remain dismally underrepresented in most cancer clinical trials, due to a variety of factors, including restrictive eligibility criteria,” Dr. Jaleh Fallah of the FDA’s Center for […]

Read more

Guideline-Concordant Multimodality Care Tied to Fewer Deaths in High-Risk Prostate Cancer

NEW YORK (Reuters Health) – In high-risk prostate cancer patients with at least one additional adverse feature, guideline-concordant multimodal care was associated with greater prostate cancer-specific survival (PCSS) in a large retrospective study. Guideline-concordant multimodal treatment was defined as radical prostatectomy (RP) with appropriate use of multimodal therapy (optimal RP); external beam radiotherapy (EBRT) with at least two years of […]

Read more

Cancer patients treated with immunotherapy at high risk of developing thrombotic complications

In a study recently published in the leading journal "Blood", Florian Moik and Cihan Ay from the Division of Hematology and Hemastasology of the Department of Medicine I of MedUni Vienna/Vienna General Hospital, working in collaboration with the Division of Oncology, the Department of Dermatology and the dispensary of Vienna General Hospital, provided preliminary data on the incidence, risk factors […]

Read more

Keratoacanthoma Symptoms

Keratoacanthoma is a slow-growing skin tumor with a characteristic type of lesion. Its appearance closely resembles that of another, more aggressive type of skin tumour called squamous cell carcinoma or SCC, and hence it should be diagnosed accurately. A squamous cell carcinoma needs to be treated immediately to contain its malignant spread. The epidermal growth called keratoacanthoma usually tends to […]

Read more

Vicious circles: Ring-shaped DNA provides cancer cells with a malignant twist

Deoxyribonucleic acid or DNA encodes information, not only in its sequence but also in its shape. Building upon previous revelatory work, a team of scientists, led by researchers at University of California San Diego, the UC San Diego branch of the Ludwig Institute for Cancer Research, Stanford University and the Howard Hughes Medical Institute, report that in cancer, distinct doughnut-shaped […]

Read more